While Novo Nordisk and Eli Lilly have soared in the past year, Roundhill Investments sees bigger gains ahead for the GLP-1 drugmakers.
This new weight loss drug ETF bets big on two of the industry’s leading players
by Elite Financial Group | May 27, 2024 | Financial Services